NICE's review of Hycamtin in cervical cancer is negative
This article was originally published in Scrip
Executive Summary
An initial cost-effectiveness assessment of GlaxoSmithKline's Hycamtin (topotecan) for the treatment of women with recurrent or stage IVb cervical cancer in England and Wales is negative.